Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 110-117

  Bowie, Christopher R ^a,d,e   McLaughlin, Danielle ^a   Carrión, Ricardo E ^a,c   Auther, Andrea M ^a   Cornblatt, Barbara A ^a,b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

High risk; Neurocognition; Pharmacological treatment; Prodrome; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ATTENTION; CHILD; COGNITION DISORDERS; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; PHOTIC STIMULATION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; STATISTICS AS TOPIC; VERBAL LEARNING; YOUNG ADULT;

EID: 84860836852     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.02.008     Document Type: Article

References (59)

1. Asarnow R.F., Steffy R.A., MacCrimmon D.J., Cleghorn J.M. An attentional assessment of foster children at risk for schizophrenia. J. Abnorm. Psychol. 1977, 86(3):267-275.
2. Beck A.T., Steer R.A., Garbin M.G. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin. Psychol. Rev. 1988, 8(1):77-100.
3. Benton A., Hamsher K., Sivan A. Multilingual Aphasia Examination 1983, AJA Associates, Iowa City, Iowa. 3rd ed.
4. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157(4):549-559.
5. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163(3):418-425.
6. Bremner J.D., Vermetten E. Neuroanatomical changes associated with pharmacotherapy in posttraumatic stress disorder. Ann. N. Y. Acad. Sci. 2004, 1032:154-157.
7. Brewer W.J., Francey S.M., Wood S.J., Jackson H.J., Pantelis C., et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 2005, 162(1):71-78.
8. Carrión R.E., Goldberg T.E., McLaughlin D., Auther A.M., Correll C.U., Cornblatt B.A. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am. J. Psychiatry 2011, 168(8):806-813.
9. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, L. Erlbaum Associates, Hillsdale, N.J.
10. Cornblatt B.A., Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J. Abnorm. Psychol. 1985, 94(4):470-486.
11. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988, 26(2):223-238.
12. Cornblatt B.A., Lencz T., Smith C.W., Correll C.U., Auther A.M., Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr. Bull. 2003, 29(4):633-651.
13. Cornblatt B.A., Lencz T., Smith C.W., Olsen R., Auther A.M., Nakayama E., et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry 2007, 68(4):546-557.
14. Correll C.U., Smith C.W., Auther A.M., McLaughlin D., Shah M., Foley C., et al. Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J. Child Adolesc. Psychopharmacol. 2008, 18(5):475-490.
15. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Repérant C., et al. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55(6):1006-1014.
16. Fiszdon J.M., Cardenas A.S., Bryson G.J., Bell M.D. Predictors of remediation success on a trained memory task. J. Nerv. Ment. Dis. 2005, 193(9):602-608.
17. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64(10):1115-1122.
18. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
19. Green M.F., Nuechterlein K.H. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr. Res. 2004, 72(1):1-3.
20. Gschwandtner U., Aston J., Borgwardt S., Drewe M., Feinendegen C., Lacher D., et al. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY). Acta Psychiatr. Scand. 2003, 108(2):152-155.
21. Gschwandtner U., Pflüger M., Aston J., Borgwardt S., Drewe M., Stieglitz R.D., Riecher-Rössler A. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 256(4):201-206.
22. Hambrecht M., Lammertink M., Klosterkötter J., Matuschek E., Pukrop R. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br. J. Psychiatry 2002, (Suppl. 43s):30-37.
23. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158(2):176-184.
24. Harvey P., Winters K., Weintraub S., Neale J.M. Distractibility in children vulnerable to psychopathology. J. Abnorm. Psychol. 1981, 90(4):298-304.
25. Harvey P.D., Green M.F., McGurk S.R., Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl.) 2003, 169:404-411.
26. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative Symptoms and Cognitive Deficits: an examination of the nature of their relationship. Schizophr. Bull. 2006, 32:250-258.
27. Hashimoto K., Fujita Y., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-I receptors. Neuropsychopharmacology 2007, 32:514-521.
28. Hawkins K.A., Addington J., Keefe R.S., Christensen B., Perkins D.O., Zipurksy R. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr. Res. 2004, 67(2-3):115-122.
29. Hawkins K.A., Keefe R.S., Christensen B.K., Addington J., Woods S.W., Callahan J., et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr. Res. 2008, 105(1-3):1-9.
30. Jahshan C., Heaton R.K., Golshan S., Cadenhead K.S. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 2010, 24(1):109-120.
31. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert. Rev. Neurother. 2008, 8(7):1101-1113.
32. Keefe R.S., Perkins D.O., Gu H., Zipursky R.B., Christensen B.K., Lieberman J.A. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 2006, 88(1-3):26-35.
33. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64(6):633-647.
34. Kirk R.E. Experimental Design: Procedures for the Behavioral Sciences 1995, Brooks/Cole Publishing, New York. 3rd ed.
35. Kovacs M. The children's depression inventory (CDI). Psychopharmacol. Bull. 1985, 21(4):995-998.
36. Lencz T., Smith C.W., Auther A., Correll C.U., Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 2004, 68(1):37-48.
37. Lencz T., Smith C.W., McLaughlin D., Auther A., Nakayama E., Hovey L., Cornblatt B.A. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry 2006, 59(9):863-871.
38. Lepage M., Buchy L., Bodnar M., Bertrand M.C., Joober R., Malla A. Cognitive insight and verbal memory in first episode psychosis. Eur. Psychiatry 2008, 23(5):368-374.
39. Levkovitz Y., Caftori R., Avital A., Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res. Bull. 2002, 58(4):345-350.
40. McGurk S.R., Twamley E.W., Sitzer D.I., McHugo G.J., Mueser K.T. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 2007, 164(12):1791-1802.
41. Medalia A., Richardson R. What predicts a good response to cognitive remediation interventions?. Schizophr. Bull. 2005, 31(4):942-953.
42. Miller T.J., McGlashan T.H., Woods S.W., Stein K., Driesen N., Corcoran C.M., Hoffman R., Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr. Q. 1999, 70(4):273-287.
43. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., Woods S.W. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 2002, 159(5):863-865.
44. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Cannon T., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., Woods S.W. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29(4):703-715.
45. Nuechterlein K.H. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J. Abnorm. Psychol. 1983, 92(1):4-28.
46. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165(2):203-213.
47. Nuechterlein K.H., Subotnik K.L., Green M.F., Ventura J., Asarnow R.F., Gitlin M.J., Yee C.M., Gretchen-Doorly D., Mintz J. Neurocognitive predictors of work outcomes in recent-onset schizophrenia. Schizophr. Bull. 2011, 37(Suppl. 2):S33-S40.
48. Orvaschel H., Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version 1994, Center for Psychological Studies, Nova Southeastern University, Fort Lauderdale, Florida.
49. Reitan R.M. Trail Making Test: Manual for Administration and Scoring 1992, Neuropsychological Laboratory, Tucson, Arizona.
50. Savitz J., van der Merwe L., Stein D.J., Solms M., Ramesar R. Genotype and childhood sexual trauma moderate neurocognitive performance: a possible role for brain-derived neurotrophic factor and apolipoprotein E variants. Biol. Psychiatry 2007, 62(5):391-399.
51. Schmitt J.A., Ramaekers J.G., Kruizinga M.J., van Boxtel M.P., Vuurman E.F., Riedel W.J. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J. Psychopharmacol. 2002, 16(3):207-214.
52. Seidman L.J., Giuliano A.J., Smith C.W., Stone W.S., Glatt S.J., Meyer E., et al. Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr. Bull. 2006, 32(3):507-524.
53. Seidman L.J., Giuliano A.J., Meyer E.C., Addington J., Cadenhead K.S., Cannon T.D., et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch. Gen. Psychiatry 2010, 67(6):578-588. North American Prodrome Longitudinal Study (NAPLS) Group.
54. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol. Psychiatry 2009, 66(6):549-553.
55. Wadsworth E.J., Moss S.C., Simpson S.A., Smith A.P. SSRIs and cognitive performance in a working sample. Hum. Psychopharmacol. 2005, 20(8):561-572.
56. Winters K.C., Stone A.A., Weintraub S., Neale J.M. Cognitive and attentional deficits in children vulnerable to psychopathology. J. Abnorm. Child Psychol. 1981, 9(4):435-453.
57. Wolf L.E., Cornblatt B.A., Roberts S.A., Shapiro B.M., Erlenmeyer-Kimling L. Wisconsin Card Sorting deficits in the offspring of schizophrenics in the New York High-Risk Project. Schizophr. Res. 2002, 57(2-3):173.
58. Woodberry K.A., Seidman L.J., Giuliano A.J., Verdi M.B., Cook W.L., McFarlane W.R. Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr. Res. 2010, 123(2-3):188-198.
59. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8(3):457-472.